Intellia Therapeutics, Inc. (NTLA) stock
NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 3/3025% above fair value
$9.70−0.85 (-8.06%)
Close on Nov 13, 2026Market cap $1.36BP/E –Yield –
Intellia Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Intellia Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$425.75M. For fiscal 2025 it was -$431.22M. The highest annual figure on record is -$13.08M in fiscal 2015.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$431.22M | – |
| FY2024 | Dec 31, 2024 | -$523.98M | – |
| FY2023 | Dec 31, 2023 | -$506.32M | – |
| FY2022 | Dec 31, 2022 | -$450.59M | – |
| FY2021 | Dec 31, 2021 | -$260.96M | – |
| FY2020 | Dec 31, 2020 | -$130.27M | – |
| FY2019 | Dec 31, 2019 | -$100.78M | – |
| FY2018 | Dec 31, 2018 | -$86.41M | – |
| FY2017 | Dec 31, 2017 | -$66.56M | – |
| FY2016 | Dec 31, 2016 | -$31.06M | – |
| FY2015 | Dec 31, 2015 | -$13.08M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$120.43M | – |
| Q2 FY2026 | Jun 30, 2026 | -$110.66M | – |
| Q1 FY2026 | Mar 31, 2026 | -$98.33M | – |
| Q4 FY2025 | Dec 31, 2025 | -$96.33M | – |
| Q3 FY2025 | Sep 30, 2025 | -$109.08M | – |
| Q2 FY2025 | Jun 30, 2025 | -$107.50M | – |
| Q1 FY2025 | Mar 31, 2025 | -$118.31M | – |
| Q4 FY2024 | Dec 31, 2024 | -$133.88M | – |
| Q3 FY2024 | Sep 30, 2024 | -$142.17M | – |
| Q2 FY2024 | Jun 30, 2024 | -$136.44M | – |
| Q1 FY2024 | Mar 31, 2024 | -$111.49M | – |
| Q4 FY2023 | Dec 31, 2023 | -$137.43M | – |
| Q3 FY2023 | Sep 30, 2023 | -$128.82M | – |
| Q2 FY2023 | Jun 30, 2023 | -$130.16M | – |
| Q1 FY2023 | Mar 31, 2023 | -$109.91M | – |
| Q4 FY2022 | Dec 31, 2022 | -$108.06M | – |
| Q3 FY2022 | Sep 30, 2022 | -$103.58M | – |
| Q2 FY2022 | Jun 30, 2022 | -$96.46M | – |
| Q1 FY2022 | Mar 31, 2022 | -$142.49M | – |
| Q4 FY2021 | Dec 31, 2021 | -$78.54M | – |
| Q3 FY2021 | Sep 30, 2021 | -$70.21M | – |
| Q2 FY2021 | Jun 30, 2021 | -$67.38M | – |
| Q1 FY2021 | Mar 31, 2021 | -$44.83M | – |
| Q4 FY2020 | Dec 31, 2020 | -$40.80M | – |
| Q3 FY2020 | Sep 30, 2020 | -$26.50M | – |
| Q2 FY2020 | Jun 30, 2020 | -$31.47M | – |
| Q1 FY2020 | Mar 31, 2020 | -$31.51M | – |
| Q4 FY2019 | Dec 31, 2019 | -$28.21M | – |
| Q3 FY2019 | Sep 30, 2019 | -$23.95M | – |
| Q2 FY2019 | Jun 30, 2019 | -$26.12M | – |
| Q1 FY2019 | Mar 31, 2019 | -$22.51M | – |
| Q4 FY2018 | Dec 31, 2018 | -$19.52M | – |
| Q3 FY2018 | Sep 30, 2018 | -$22.95M | – |
| Q2 FY2018 | Jun 30, 2018 | -$22.52M | – |
| Q1 FY2018 | Mar 31, 2018 | -$21.42M | – |
| Q4 FY2017 | Dec 31, 2017 | -$23.88M | – |
| Q3 FY2017 | Sep 30, 2017 | -$15.09M | – |
| Q2 FY2017 | Jun 30, 2017 | -$15.31M | – |
| Q1 FY2017 | Mar 31, 2017 | -$12.29M | – |
| Q4 FY2016 | Dec 31, 2016 | -$10.42M | – |
See a number that looks wrong?